GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial ...

Sanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately held back development of a multiple sclerosis drug to avoid payments ...

Genzyme (Cambridge, MA) acquired Cell Genesys (Foster City, CA), a firm with a large patent estate for gene therapy, clinical-stage cancer drugs, and novel gene activation technology, in October ...

The company remains convinced of the product's merits and—bolstered by the backing of a $1.38 billion deal from Genzyme a year ago—continues to pursue cardiac and other autoimmune indications.

Genzyme continued to drive growth for Sanofi in the first quarter, helped along by the company’s vaccines unit, but diabetes drugs are still struggling. Net sales were €8,391 million ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Strategic Collaborations: The company's ability to establish and maintain collaborations, such as the prior agreement with ...

SAN ANTONIO, November 04, 2024--bioAffinity Technologies promotes Senior VP William Bauta, Ph.D., to Chief Science Officer to spearhead product development.

Affinity Technologies (BIAF) announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in ...

[17] Nanotechnology-based methods of drug delivery across the BBB include two commercialized technologies LipoBridge™ (Genzyme Pharmaceuticals, MA, USA) and G-Technology® (to-BBB, Leiden ...

National Comprehensive Cancer Network (NCCN) presents preliminary data from a study demonstrating the usability of the Health ...

The 43 patients treated with ravulizumab had a 33.2% greater reduction in average urine protein to creatinine ratio (UPCR) ...